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Incidence of uveitis and macular edema
among patients taking fingolimod 0.5 mg
for multiple sclerosis
Scott Joseph Sonne1 and Bradley Thomas Smith2,3*
Abstract
Background: Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general
population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema
and thus requires ophthalmic examination. However, murine models and anecdotal reports suggest fingolimod
may reduce the incidence of uveitis.
Purpose: To report the incidence of uveitis and macular edema among those on fingolimod 0.5 mg (Gilenya®)
therapy for multiple sclerosis (MS).
Methods: Retrospective review of patients on fingolimod who developed uveitis and/or macular edema.
Results: No patients had an occurrence or history of uveitis. Four of the 188 (2.13%) patients developed macular
edema without ocular inflammation. One of the 188 (0.53%) patients developed Acute Macular Neuroretinopathy.
Conclusion: Patients taking fingolimod have a lower incidence of uveitis than expected in a population of MS
patients.
Keywords: Cystoid macular edema, Macular edema, Uveitis, Multiple sclerosis, Acute macular neuroretinopathy,
Fingolimod, Gilenya
Background
Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease which targets the central nervous system in a
delayed-type hypersensitivity reaction. Fingolimod (Gile-
nya®, Novartis) reduces both the number of relapses and
progression of disease in the relapsing remitting variant
of MS by preventing the migration of lymphocytes [1, 2].
Fingolimod-associated macular edema (FAME) is a
known complication requiring ophthalmic examination
[3–5]. Uveitis can cause vision loss and may be 20 times
more likely in MS when compared to the general popu-
lation [6–11]. The recommendation of pretreatment
ophthalmic exams and monitoring while on fingolimod
presents a unique opportunity to evaluate MS patients
who may have undiagnosed uveitis and to follow for its
development.
Herein we report an incidence of uveitis and macular
edema among patients on the FDA-approved dose of
fingolimod 0.5 mg for MS.
Main text
Methods
The electronic health record at The Retina Institute (St.
Louis) was reviewed for patients referred for screening
exams due to fingolimod use. Each case was examined
for a past history, recurrence, or new occurrence of uve-
itis. Snellen visual acuity was reviewed as well as time of
exposure to fingolimod. Optical coherence tomography
(OCT) and biomicroscopy results were available for all
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patients. The incidence of optic neuritis, FAME, and
other visually significant ocular comorbidities were also
recorded.
Results
A total of 188 patients met the study criteria over a period
of 104months. None had or developed uveitis [6–11].
One of the 188 (0.53%) developed acute macular neurore-
tinopathy (AMN). Twenty six of 188 (13.83%) had a his-
tory of optic neuritis and 7 (3.7%) had a new occurrence
during the course of the study. The mean follow up on
fingolimod was 60.9months with a range of 1–104
months. Three patients discontinued treatment after 57,
43, and 13months due to nonophthalmic reasons. Visual
acuity (VA) was 20/40 or better in 93% of eyes, 5% had
visual acuity 20/50 to 20/200, and 2% had worse VA than
20/200. The visual acuity of two eyes was worse than 20/
400 as a result of optic neuritis. Additional causes of vision
loss in the patients with vision worse than 20/100 were
optic neuritis, ischemic optic neuropathy, ruptured globe,
keratoconus, macular hole, and amblyopia.
Fingolimod-associated macular edema (FAME)
Three of the 188 patients (1.6%) developed FAME
(Fig. 1). Fingolimod was continued and each was suc-
cessfully treated with either topical steroids, NSAIDs, or
a combination of the two. None of these patients had
any other identifiable cause of macular edema. Another
65-year-old female with a 57 month exposure to fingoli-
mod developed macular edema 2 weeks after cataract ex-
traction. She was successfully treated with topical and
subtenons steroids while continuing the fingolimod.
Uveitis
No patient had a history of or developed uveitis during
the follow up period.
Other findings
One 27-year-old female presented with unilateral photo-
psia and a paracentral scotoma 5months after beginning
fingolimod. Her migraines were treated with sumatriptan
and she took lisdexamfetamine for weight control.
Otherwise, she denied recent viral prodrome,
Fig. 1 A 58 yo female with a 9 month history of fingolimod developed macular edema in her left eye. She responded to bromfenac topical
drops used twice daily although she continued fingolimod. Normal macular contour is demonstrated on OCT at the initial screening visit (a) OCT
demonstrates FAME at the 9 month follow up visit (b) OCT after 6 weeks shows reduction in the edema (c)
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vaccinations, pregnancy, oral contraceptive pills (OCPs),
and international travel. VA was 20/20 and dilated fun-
dus examination revealed a subtle reddish lesion just su-
perior to the fovea of the right eye consistent with acute
macular neuroretinopathy (Fig. 2). The patient’s visual
defect faded and the flashes of light resolved by 5
months after presentation. She remained stable through-
out her 13 months of follow up.
Discussion
The incidence of uveitis in this cohort (n = 188) using
fingolimod for MS was zero. The incidence of uveitis in
MS patients is variable yet none in our cohort had a typ-
ical uveitis occurrence despite a mean observation
period greater than 5 years [6–9, 12–16]. Lim et al. pre-
viously pooled data on the incidence of uveitis from the
MS fingolimod studies [12]. The mean observation
period was 627 days and included a range of fingolimod
doses compared with placebo and interferon beta-1a.
The authors reported a first time uveitis occurrence in
0.09% of patients on fingolimod (dose range 0.5 mg to 5
mg), 0.2% in the placebo group, and 0.09% in the inter-
feron group. Of the 139 with a uveitis history, 5 (3.6%)
had recurrence while on fingolimod. One in 8 (12.5%)
patients on placebo had recurrence while 4 of 15
(26.67%) taking interferon had recurrent uveitis. Though
the MS fingolimod studies were not designed to evaluate
the effect of fingolimod on the prevention of uveitis or a
reduction in uveitis recurrence, the data suggest those
on placebo had double the rate of uveitis occurrence
compared with those on fingolimod. Those taking intra-
muscular interferon had a similar rate of first time uve-
itis. The rate of recurrent uveitis in those taking a
placebo was over 3 times those on fingolimod, while re-
currence in those taking interferon was just over 7 times
those on fingolimod. In the last 8 years since we began
Fig. 2 A 27 yo female on fingolimod developed Acute Macular Neuroretinopathy (AMN) 5 months after initiating treatment. Optical coherence
tomography (OCT) reveals natural history of AMN, seen as hyperreflectivity of the outer plexiform layer with secondary involvement of the
ellipsoid layer and external limiting membrane (a) Subtle reddish parafoveal lesion is shown on color fundus image yet better visualized as a
petalloid lesion with multicolor imaging (b) Choriocapillaris OCT angiography shows a filling defect (c) Retinal nerve fiber layer OCT is within
normal limits (d)
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screening patients on fingolimod we noted an unusually
low incidence of concomitant uveitis despite the diagno-
sis of MS. We cannot comment on the rate of recur-
rence since none of our cohort had a prior history of
uveitis. However, this retrospective review confirms a
low initial occurrence of uveitis in patients taking fingo-
limod for MS. Varying doses of fingolimod and inter-
feron beta-1a were included in the data compiled by Lim
et al. [12]. Our current study is unique in that it includes
only the FDA-approved 0.5 mg dose of fingolimod. In
addition, the cohort is a relatively homogenous group
without a history of uveitis who were observed for a sig-
nificantly longer period (mean > 5 years).
Fingolimod limits lymphocytic migration by targeting
sphingosine-1-phosphate (S1P) receptors found in
lymphocytic tissue, endothelium, and leukocytes [1, 2,
17]. It is therefore not unreasonable to hypothesize that
there is a limitation of lymphocytic migration through
the blood-retinal barrier as well when patients are ex-
posed to fingolimod. There is precedence for fingoli-
mod’s ophthalmic anti-inflammatory effect in
experimental autoimmune uveitis. Murine studies have
confirmed active disease suppression, maintenance of
disease remission, and increased vascular barrier integ-
rity when subjects are exposed to fingolimod [18, 19].
We hypothesize fingolimod’s anti-inflammatory effect
could partly explain the lack of uveitis in our cohort that
would typically be associated with MS.
One patient developed AMN. There is no consensus
on a unifying mechanism of AMN though it is most
strongly associated with flu-like illnesses, influenza vac-
cination, and OCP’s [20–25]. The patient in our cohort
had other risk factors for AMN including lisdexamfeta-
mine and migraine headaches. Lisdexamfetamine acts by
facilitating the release of norepinephrine and dopamine,
known vasoconstrictors. Therefore, her AMN was likely
due to relative ischemia from vasoconstriction rather
than a manifestation of inflammation within the retinal
vasculature. The latter seems unlikely since she nor any
other patient in our cohort developed typical clinical
findings consistent with uveitis. There is no known dir-
ect link between AMN and MS alone, although it has
been associated with acute demyelinating optic neuritis
[26, 27]. In a prospective study of 114 patients with
acute optic neuritis, Deschamps et al. found 6 developed
AMN [27]. Therefore it remains that the development of
AMN in our patient is likely coincidental since she had
no history of optic neuritis.
The average time to the development of uveitis after
an MS diagnosis ranges from 3.6 to 9 years [6–9]. We
did not include time since the onset of MS diagnosis
since this information was not available on every patient.
Yet the mean follow up on fingolimod was 60.9 months
and was likely adequate considering the average onset of
uveitis after MS. Further, the length of time of MS was
at least the same or greater than the fingolimod expos-
ure (mean = 60.9 months) since MS was the indication
for fingolimod use in all patients.
FAME occurred in 3 of the 188 (1.6%) patients in the
present study. This rate is much higher than the previ-
ously documented 0.2% incidence [3, 4, 28]. The mech-
anism of FAME is not fully understood although it
develops within 3 months from initiation of fingolimod
therapy in 68% of cases [3, 4]. It has been shown to de-
crease vascular permeability yet it also increases tight
junction permeability resulting in edema formation [1,
29]. The incidence of FAME in those with a history of
uveitis was 19% compared with 1% in the FREEDOMS
and TRANSFORMS trials in patients taking the 1.25 mg
dose of fingolimod [29]. This data suggests a link be-
tween uveitis and FAME although there may be a vari-
able effect on vascular permeability that is dependent on
the individual’s immune system status [2, 4]. It is pos-
sible that those with a history of uveitis may have weak-
ened tight junctions, resulting in a predilection for
FAME with S1P receptor activation rather than vascular
barrier stabilization [29]. The decreased dose (0.5 mg) of
fingolimod now FDA-approved for the treatment of MS
may not have such a high association of uveitis and
FAME. Our patients with FAME had no history of uve-
itis or indications of intraocular inflammation, though
subclinical uveitis cannot be ruled out in the absence of
fluorescein angiography. There was an increased inci-
dence of FAME in this cohort and all cases responded to
anti-inflammatory therapy despite continuation of
fingolimod.
The strengths of this study include a uniquely long fol-
low up period with a mean of over 5 years, the
generalizability of the findings due to exposure to the
only FDA-approved dose of fingolimod for adults, and
the consistency of examination by ophthalmologists with
experience in the evaluation and treatment of anterior,
intermediate, and posterior uveitis. No patients were ex-
cluded from taking fingolimod. However, as a retro-
spective review it is possible the referring pattern of the
treating neurologists may have introduced some selec-
tion bias. This did not occur to our knowledge since the
determination of ocular contraindication to fingolimod
treatment was the responsibility of the examining
ophthalmologist.
Conclusions
Fingolimod is a well tolerated drug. Despite the high in-
cidence of FAME in our cohort it was easily managed
with topical therapy. We report a zero incidence of first
time uveitis typically associated with MS in patients tak-
ing fingolimod and call for further evaluation of its po-
tential use in the management of uveitis.
Sonne and Smith Journal of Ophthalmic Inflammation and Infection           (2020) 10:24 Page 4 of 5
Abbreviations
MS: Multiple sclerosis; FAME: Fingolimod-associated macular edema;
OCT: Optical coherence tomography; AMN: Acute macular neuroretinopathy;





SJS acquired the data and participated in its analysis and interpretation. He
drafted the manuscript and gathered the pertinent references. BTS was
responsible for the conception and design, interpretation of data, and
revision of the manuscript. He expertly reviewed the particular cases of note
and provided interpretation of images. Both authors edited and approved
the final manuscript.
Funding
Provided in part by the Retina Research and Development Foundation.
Availability of data and materials
Data was collected using the electronic health record of The Retina Institute
in St. Louis. The datasets generated contain health protected information
and are therefore not available to the public.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board at St. Luke’s
Hospital. Data collection was conducted in a HIPPA compliant fashion and
the research adhered to the tenets of the World Medical Association’s
Declaration of Helsinki.
Consent for publication
Informed consent was not sought for the present study because no
identifiable images or data were used.
Competing interests
The authors declare no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.
Author details
1St. Louis University School of Medicine, St. Louis, USA. 2The Retina Institute
in St. Louis, 2201 S Brentwood Blvd, St. Louis, MO 63144, USA. 3Department
of Ophthalmology and Visual Sciences, Washington University, St. Louis, USA.
Received: 9 March 2020 Accepted: 3 September 2020
References
1. McVerry BJ, Garcia JG (2004) Endothelial cell barrier regulation by
sphingosine 1-phosphate. J Cell Biochem 92:1075–1085
2. Mandal P, Gupta A, Fusi-Rubiano W et al (2017) Fingolimod: therapeutic
mechanisms and ocular adverse effects. Eye (Lond) 31:232–240
3. Kappos L, Radue EW, O’Connor P et al (2010) A placebo controlled trial of
oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401
4. Zarbin MA, Jampol LM, Jager RD et al (2013) Ophthalmic evaluations in
clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology
120:1432–1439
5. Budde K, Schütz M, Glander P et al (2006) FTY720 (fingolimod) in renal
transplantation. Clin Transpl 20:17–24
6. Kaya D, Kaya M, Özakbaş S, Idiman E (2014) Uveitis associated with multiple
sclerosis: complications and visual prognosis. Int J Ophthalmol 7:1010–1013
7. Le Scanff J, Seve P, Renoux C et al (2008) Uveitis associated with multiple
sclerosis. Mult Scler 14:415–417
8. Thouvenot E, Mura F, De Verdal M et al (2012) Ipsilateral uveitis and optic
neuritis in multiple sclerosis. Mult Scler Int 2012:37236
9. Biousse V, Trichet C, Bloch-Michel E, Roullet E (1999) Multiple sclerosis
associated with uveitis in two large clinic-based series. Neurology 52:179–
181
10. Jouve L, Benrabah R, Héron E et al (2017) Multiple sclerosis-related uveitis:
does MS treatment affect uveitis course? Ocul Immunol Inflamm 25:302–
307
11. Zein G, Berta A, Foster CS (2004) Multiple sclerosis-associated uveitis. Ocul
Immunol Inflamm 12:137–142
12. Lim LL, Silva DG, Lo TC et al (2019) Uveitis in patients with multiple sclerosis
in clinical trials of fingolimod: incidence, prevalence, and impact on disease
course. Ophthalmology 126:438–444
13. Porter R (1972) Uveitis in association with multiple sclerosis. Br J
Ophthalmol 56:478–481
14. Graham EM, Francis DA, Sanders MD, Rudge P (1989) Ocular inflammatory
changes in established multiple sclerosis. J Neurol Neurosurg Psychiatry 52:
1360–1363
15. Karara AM, Macky TA, Sharawy MH (2013) Pattern of uveitis in an Egyptian
population with multiple sclerosis: a hospital-based study. Ophthalmic Res
49:25–29
16. Vidović T, Cerovski B, Jukić T (2005) The appearance of pars planitis in
multiple sclerosis. Coll Antropol 29:203–206
17. David OJ, Kovarik JM, Schmouder RL (2012) Clinical pharmacokinetics of
fingolimod. Clin Pharmacokinet 51:15–28
18. Raveney BJE, Copland DA, Nicholson LB, Dick AD (2008) Fingolimod
(FTY720) as an acute rescue therapy for intraocular inflammatory disease.
Arch Ophthalmol 126:1390–1395
19. Copland DA, Liu J, Schewitz-Bowers LP et al (2012) Therapeutic dosing of
fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular
inflammation, and maintains the blood-ocular barrier. Am J Pathol 180:672–
681
20. Turbeville SD, Cowan LD, Gass JD (2003) Acute macular neuroretinopathy: a
review of the literature. Surv Ophthalmol 48:1–11
21. Bhavsar KV, Lin S, Rahimy E et al (2016) Acute macular neuroretinopathy: a
comprehensive review of the literature. Surv Ophthalmol 61:538–565
22. Rahimy E, Sarra D (2014) Paracentral acute middle maculopathy spectral-
domain optical coherence tomography feature of deep capillary ischemia.
Curr Opin Ophthalmol 3:207–212
23. Casalino G, Arrigo A, Romano F (2019) Acute macular neuroretinopathy:
pathogenic insights from optical coherence tomography angiography. Br J
Ophthalmol 103:410
24. Munk MR, Jampo LM, Cunha Souza E et al (2016) New associations of
classic acute macular neuroretinopathy. Br J Ophthamol 100:389–394
25. Shah SP, Goren JF, Lazzara MD et al (2013) Aute macular neuroretinopathy
associated with the use of norepinephrine reuptake inhibitors: a case series
and OCT findings. Retin Cases Brief Rep 7:146–149
26. Foroozan R, Buono LM, Savino PJ, Sergott RC (2002) Acute demyelinating
optic neuritis. Curr Opin Ophthalmol 13:375–380
27. Deschamps R, Vasseur V, Shor N et al (2019) A new association: acute
macular neuroretinopathy in acute optic neuritis. Acta Ophthalmol 97:e753–
e756
28. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular
interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415
29. Cugati S, Chen CS, Lake S, Lee AW (2014) Fingolimod and macular edema:
pathophysiology, diagnosis, and management. Neurol Clin Pract 4:402–409
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sonne and Smith Journal of Ophthalmic Inflammation and Infection           (2020) 10:24 Page 5 of 5
